Revolution Medicines shared early Phase 1/2 results for zoldonrasib combination regimens in RAS-G12D metastatic pancreatic ductal adenocarcinoma. In the report, the company’s zoldonrasib plus standard mFOLFIRINOX achieved an overall response rate of 82% in patients carrying the RAS-G12D mutation, with the company planning additional Phase 3 testing. The coverage also described a second ESMO Gastrointestinal Cancers Congress readout of a zoldonrasib plus daraxonrasib combination, reporting a 50% response rate in a metastatic PDAC setting. Analysts cited response levels as comparatively favorable versus chemotherapy expectations for similar populations. Revolution also launched the Phase 3 RASolute 305 study, testing zoldonrasib with mFOLFIRINOX as a frontline treatment for PDAC, with a primary completion date listed for December 2028. Why it matters: if response rates hold and safety remains manageable, RAS-G12D–directed combinations could challenge the current sequencing of therapy in a disease area with limited durable options.